Table 7.

Subgroup analysis of modified objective response rate (ORR) and grade 3–4 adverse effects rate (grade 3–4 AEs%) of nivolumab in non‐small‐cell lung cancer (NSCLC) patients

Group	ORR				Grade 3–4 AEs%
	No. of studies	ES (95% CI)	P heterogeneity	I 2 (%)	No. of studies	ES (95% CI)	P heterogeneity	I 2 (%)
Total	13	18% (15–20%)	0.235	20.6	13	12% (9–16%)	<0.001	89.1
Study design
Randomized open‐label study	2	19% (16–23%)	0.374	0.0	3	12% (6–18%)	0.002	84.0
Noncomparative open‐label cohort study	11	17% (15–20%)	0.192	26.4	10	13% (8–17%)	<0.001	88.7
Medication type
Nivolumab	10	17% (15–19%)	0.352	9.9	12	12% (8–16%)	<0.001	89.4
Nivolumab with other drugsa	3	22% (13–31%)	0.183	41.4	1	25% (10–40%)	NR	NR
Program subgroup
Subgroupb therapy	5	19% (15–24%)	0.356	8.9	2	17% (7–27%)	0.176	45.3
No subgroup therapy	8	17% (15–19%)	0.195	29.2	11	12% (8–16%)	<0.001	89.8
Region
North America	12	18% (15–20%)	0.185	26.4	11	14% (9–19%)	<0.001	90.7
Europe	1	18% (14–22%)	NR	NR	2	5% (3–8%)	0.949	0.0
Study phase
I	7	18% (14–22%)	0.199	30.1	4	14% (3–24%)	<0.001	84.6
II	3	16% (10–21%)	0.145	48.3	4	17% (13–21%)	0.638	0.0
III	3	19% (16–22%)	0.872	0.0	5	9% (5–13%)	<0.001	84.6
Histology
Squamous	4	16% (13–20%)	0.231	30.2	4	10% (5–16%)	0.001	81.3
Nonsquamous	1	19% (15–24%)	NR	NR	2	16% (4–27%)	0.018	82.2
Mixed histologyc	8	19% (15–22%)	0.203	28.3	7	13% (6–20%)	<0.001	92.1

ES, Effect size (main outcome such as ORR or Grade 3–4 AEs% with corrected standard deviation); NR, no relevant statistic data.

^aIpilimumab, bevacizumab, platinum‐based doublet chemotherapy (gemcitabine, cisplatin, pemetrexed, carboplatin, paclitaxel).

^bThe study contained different nivolumab therapy strategy of various dosage and duration et al.

^cSquamous, nonsquamous, adenocarcinoma, unknown types etc.